vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Orchid Island Capital, Inc. (ORC). Click either name above to swap in a different company.
Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $38.3M, roughly 1.0× ImmunityBio, Inc.). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -161.8%, a 430.5% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 372.6%).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
IBRX vs ORC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $38.5M |
| Net Profit | $-61.9M | $103.4M |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | — |
| Net Margin | -161.8% | 268.7% |
| Revenue YoY | 407.0% | 372.6% |
| Net Profit YoY | -4.7% | 1764.9% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $38.5M | ||
| Q3 25 | $32.1M | $26.9M | ||
| Q2 25 | $26.4M | $23.2M | ||
| Q1 25 | $16.5M | $19.7M | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $6.1M | $340.0K | ||
| Q2 24 | — | $-697.0K | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | $-61.9M | $103.4M | ||
| Q3 25 | $-67.3M | $72.1M | ||
| Q2 25 | $-92.6M | $-33.6M | ||
| Q1 25 | $-129.6M | $17.1M | ||
| Q4 24 | $-59.2M | — | ||
| Q3 24 | $-85.7M | $17.3M | ||
| Q2 24 | — | $-5.0M | ||
| Q1 24 | — | $19.8M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | — | ||
| Q3 25 | -173.5% | — | ||
| Q2 25 | -269.8% | — | ||
| Q1 25 | -390.1% | — | ||
| Q4 24 | -919.0% | — | ||
| Q3 24 | -1314.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -161.8% | 268.7% | ||
| Q3 25 | -209.8% | 267.8% | ||
| Q2 25 | -350.3% | -145.0% | ||
| Q1 25 | -784.9% | 86.9% | ||
| Q4 24 | -783.4% | — | ||
| Q3 24 | -1404.0% | 5094.1% | ||
| Q2 24 | — | 714.3% | ||
| Q1 24 | — | -794.2% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $-0.08 | — | ||
| Q3 24 | $-0.14 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $665.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $1.4B |
| Total Assets | $501.9M | $11.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $665.9M | ||
| Q3 25 | $257.8M | $583.9M | ||
| Q2 25 | $153.7M | $440.8M | ||
| Q1 25 | $61.6M | $396.4M | ||
| Q4 24 | $149.8M | — | ||
| Q3 24 | $130.4M | $322.1M | ||
| Q2 24 | — | $241.0M | ||
| Q1 24 | — | $190.4M |
| Q4 25 | $-500.5M | $1.4B | ||
| Q3 25 | $-524.3M | $1.1B | ||
| Q2 25 | $-570.7M | $912.0M | ||
| Q1 25 | $-591.4M | $855.9M | ||
| Q4 24 | $-489.1M | — | ||
| Q3 24 | $-745.1M | $656.0M | ||
| Q2 24 | — | $555.9M | ||
| Q1 24 | — | $481.6M |
| Q4 25 | $501.9M | $11.7B | ||
| Q3 25 | $519.0M | $9.1B | ||
| Q2 25 | $402.1M | $7.6B | ||
| Q1 25 | $303.8M | $7.3B | ||
| Q4 24 | $382.9M | — | ||
| Q3 24 | $364.6M | $5.9B | ||
| Q2 24 | — | $4.9B | ||
| Q1 24 | — | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $120.4M |
| Free Cash FlowOCF − Capex | $-71.3M | — |
| FCF MarginFCF / Revenue | -186.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | 1.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $120.4M | ||
| Q3 25 | $-68.9M | $28.0M | ||
| Q2 25 | $-79.7M | $18.4M | ||
| Q1 25 | $-85.9M | $25.8M | ||
| Q4 24 | $-85.1M | — | ||
| Q3 24 | $-98.8M | $-14.8M | ||
| Q2 24 | — | $19.3M | ||
| Q1 24 | — | $45.0M |
| Q4 25 | $-71.3M | — | ||
| Q3 25 | $-69.6M | — | ||
| Q2 25 | $-80.8M | — | ||
| Q1 25 | $-87.0M | — | ||
| Q4 24 | $-87.3M | — | ||
| Q3 24 | $-101.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -186.2% | — | ||
| Q3 25 | -217.2% | — | ||
| Q2 25 | -305.9% | — | ||
| Q1 25 | -526.9% | — | ||
| Q4 24 | -1155.4% | — | ||
| Q3 24 | -1663.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.16× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.51× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
